DIPHTHERIA TOXOID

Bladder Cancer

National Cancer Institute (NCI)vaccinePhase 2Dormant

CCC

51/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 73/ 100

Competitive context

122 Active assets in the Bladder Cancer cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II G1 Therapeutics, Inc.	Phase 3	BBB
TRASTUZUMAB NKGen Biotech, Inc.	Phase 2	BB
Carboplatin G1 Therapeutics, Inc.	Phase 3	BB
VINBLASTINE University of Southern California	Phase 3	BB
Pembrolizumab Essen Biotech	Phase 3	BB

View all 50 →

Same molecule, other indications

DIPHTHERIA TOXOID is also rated in:

relapsing-remitting multiple sclerosisDormant

B

Indicative ·

59 / 100

multiple sclerosisDormant

CCC

Indicative ·

54 / 100

fallopian tube carcinomaDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.